On February 23, 2017, pre-market, Boston Scientific revealed a voluntary recall of its range of Lotus Valve heart devices, naming reports of an early release of a pin that connects the heart valve device to the delivery system. Boston Scientific said that it believes the problem is caused by "excess tension in the pin mechanism introduced during the manufacturing process" and anticipates bringing the products back on the market in 2017's fourth quarter. Following this news, Boston Scientific stock has dropped as much as $1.87 per share, or 7.43%, during intraday trading on February 23, 2017.
If you are aware of any facts relating to this investigation, or purchased shares of Boston Scientific, you can assist this investigation by visiting the firm's site: www.bgandg.com/bsx. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | firstname.lastname@example.org
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert-bronstein-gewirtz--grossman-llc-announces-investigation-of-boston-scientific-corp-bsx-300412660.html
SOURCE Bronstein, Gewirtz & Grossman, LLC